Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086593 · ClinicalTrials.gov registry record · Phase 3
Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 209
- Enrollment target
NCT00086593 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 209 participants.
The verdict
NCT00086593, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 209 participants
- Enrollment target
Study Summary
This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be randomized to receive either an FDA-approved drug or placebo in addition to the current treatment. Safety will be closely monitored through vital signs, various tests, and blood and urine samples.
Interventions
- DRUG lamotrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00086593
The ClinicalTrials.gov registry entry for NCT00086593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 209 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which lamotrigine is the first listed.
NCT00086593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00086593 about?
NCT00086593 is a clinical study titled "Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia". This is a 12-week study for the treatment of chronic persistent symptoms in participants with schizophrenia. Participants on a stable, optimal dose of up to two atypical antipsychotics who fulfill the screening criteria will be randomized to receive either an FDA-approved drug or placebo in addition...
What is the current status of trial NCT00086593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 209 participants. The study started on 2004-05. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00086593?
The interventions under investigation include: lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00086593?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.